Sea buckthorn leaves contain nutritionally and pharmacologically relevant compounds but are limited by strong bitterness and astringency that reduce consumer acceptance. The study aimed to determine how fermentation alters the flavor profile of sea buckthorn leaf tea (SBLT) and to predict whether the bitter constituents released or modified by processing have potential anti–type 2 diabetes (T2DM) actions. The work combined sensory evaluation, chromatographic profiling, molecular docking, and network pharmacology approaches to link flavor chemistry with putative bioactivity.
Sensory assessment reported a marked transformation in aroma and oral sensation after fermentation. The aroma shifted from a primarily fresh, grassy character toward a more complex bouquet described as roasted, caramel and woody. Concurrently, fermentation attenuated perceived bitterness and astringency, improving the sensory quality of SBLT. The abstract does not provide detailed sensory panel methodology, scoring scales, or the number of panelists; those experimental details were not reported in the source abstract.
Chromatographic analyses identified nineteen compounds as key contributors to aroma changes after fermentation. Among these, 2-ethyl-3,5-dimethylpyrazine and 2-furylmethanol were highlighted as representative markers of the roasted and caramel-like notes associated with fermentation. The abstract lists the number of key aroma compounds and two marker molecules but does not present full compound lists, absolute concentrations, or analytical methods in the abstract itself; those specifics were not reported in the source abstract.
A central chemical mechanism proposed for the reduction in bitterness and astringency was the hydrolysis of flavonoid glycosides into their corresponding aglycones during fermentation. This conversion is consistent with decreased perceived bitterness because glycosylation state influences taste perception and solubility. The abstract attributes the sensory improvement primarily to this biochemical change; however, detailed enzymatic pathways, fermentation conditions, or quantitative changes in individual flavonoid glycosides and aglycones are not provided in the abstract.
Correlation analyses identified thirteen core constituents that strongly associated with the bitterness attribute of SBLT. Notable among these were epicatechin and procyanidin B2, both known flavan-3-ols that can elicit bitter and astringent sensations. These constituents were singled out as primary contributors to the aversive taste profile prior to fermentation. The abstract does not specify the full list of thirteen compounds, their relative abundances, or the statistical thresholds used for correlation.
Molecular docking experiments were used to probe interactions between the identified bitter molecules and human bitter taste receptors. The bitter constituents showed substantial predicted binding affinities with TAS2R14 and TAS2R39, with reported docking energies reaching as low as −8.5 kcal·mol−1. These in silico results support the role of the listed compounds in activating bitter taste receptors, helping to explain the organoleptic profile. The abstract does not include docking protocols, receptor models, or validation steps beyond the reported binding energies.
A network pharmacology analysis linked the core bitter constituents to a broad set of T2DM-related molecular targets. The bitter compounds were predicted to collectively target 874 nodes relevant to T2DM pathophysiology. Key signaling pathways implicated included the phosphoinositide 3-kinase–Akt (PI3K–Akt) pathway and the tumor necrosis factor (TNF) signaling pathway. Prominent hub targets noted in the abstract were AKT1, interleukin-6 (IL-6) and GAPDH, pointing toward combined anti-inflammatory and glucose-regulatory mechanisms. While this multi-target framework provides a theoretical basis for potential benefit in T2DM, the abstract describes in silico predictions only; experimental validation in cellular or animal models was not reported in the abstract.
The authors conclude that fermentation is an effective processing strategy to improve the sensory quality of SBLT by reducing bitterness and enhancing roasted aromas. At the same time, the bitter constituents—many of which decrease in glycosylated form during fermentation—are predicted by docking and network pharmacology to engage multiple T2DM-related targets and pathways, suggesting anti-inflammatory and glucose-regulatory potential. These findings provide a theoretical, multi-target rationale for considering SBLT as a functional dietary intervention in T2DM.
Translational gaps and limitations apparent from the abstract: the report focuses on sensory, chemical profiling and in silico predictions; it does not include reported in vitro or in vivo efficacy data for glycoside-derived aglycones or the individual bitter compounds, nor does it detail fermentation parameters, analytical quantitation, or sensory panel methodology in the abstract. Those experimental details and biological validations were not reported in the source abstract and would be necessary to move from theoretical prediction to clinical or nutritional recommendations.